Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia
- 74 Downloads
Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children. Here, the RSV fusion (F) glycoprotein epitope FFL was redesigned based on its complex crystal structure with motavizumab, an mAb drug in development for the prevention of RSV infections, aiming to obtain therapeutic peptide vaccines with high affinity to induce RSV-specific neutralizing antibodies. Computational modeling and analysis found that only a small region covering the helix-turn-helix (HTH) motif of FFL can directly interact with motavizumab and confer stability and specificity to the complex system, while the rest of the epitope primarily serves as a structural scaffold that stabilizes the HTH conformation of motavizumab-binding site. Molecular dynamics simulations revealed a large flexibility and intrinsic disorder for the isolated linear HTH peptide, which would incur a considerable entropy penalty upon binding to motavizumab. In this respect, the FFL epitope was redesigned by truncation, mutation, and cyclization to derive a number of small cyclic peptide immunogens. We also employed in vitro fluorescence-based assays to demonstrate that the linear epitope peptide has no observable affinity to motavizumab, whereas redesigned versions of the peptide can bind with a moderate or high potency.
KeywordsRespiratory syncytial virus Fusion glycoprotein epitope Rational peptide vaccine design Pediatric pneumonia
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest.
- 5.Mejías A, Ramilo O (2008) Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2:433–439Google Scholar
- 6.Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA (2011) Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203:674–682CrossRefGoogle Scholar
- 7.Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe Jr JE, Johnson PR, Schief WR (2014) Proof of principle for epitope-focused vaccine design. Nature 507:201–206CrossRefGoogle Scholar
- 8.Ni H, Zhuang Y, Chen Z, Ji W (2017) Molecular engineering of respiratory syncytial virus immunogen against pediatric viral pneumonia. Mol. Simul. 44:1–6Google Scholar
- 13.Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang J, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 24:1999–2012CrossRefGoogle Scholar
- 22.Zhou P, Zhang S, Wang Y, Yang C, Huang J (2016) Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. J. Biomol. Struct. Dyn. 34:1806–1817CrossRefGoogle Scholar
- 31.Luo H, Du T, Zhou P, Yang L, Mei H, Ng H, Zhang W, Shu M, Tong W, Shi L, Mendrick DL, Hong H (2015) Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. Comb. Chem. High Throughput Screen. 18:296–304CrossRefGoogle Scholar
- 36.Zhou P, Hou S, Bai Z, Li Z, Wang H, Chen Z, Meng Y (2017) Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands. Artif Cells Nanomed Biotechnol. https://doi.org/10.1080/21691401.2017.1360327